Myovant Sciences Ltd (NYSE:MYOV) shares are trading significantly lower Tuesday after the company and Pfizer Inc (NYSE:PFE) announced an update on the Supplemental New Drug Application for MYFEMBREE for the management of moderate to severe pain associated with endometriosis.
In accordance with the ongoing review of the application, on April 6, the FDA provided notice to the companies that it identified deficiencies that preclude discussion of labeling and/or post-marketing requirements and commitments.
